Autonomix Medical, Inc. announced on September 3, 2025, new longer-term post hoc data from its initial phase of the first-in-human proof-of-concept (PoC 1) study. The analysis demonstrated sustained pain reduction, significant quality of life gains, and 100% zero opioid use in patients with severe pancreatic cancer pain.
Results from responders (n=6) showed a long-lasting, durable pain reduction of nearly 66%, corresponding to a mean 5.08 reduction on the Visual Analog Scale (VAS) pain scale. Critically, 100% of responders (n=7) achieved zero opioid use at their 3-month post-procedure follow-up, reinforcing the potential of this non-opioid alternative.
Quality of life markers further improved, including sleep quality, energy level, and the ability to engage in normal daily and leisure activities, alongside reduced tension, vomiting, and constipation. These data build on previous findings, showing statistically significant pain relief as early as 24 hours post-procedure (p<0.001) and sustained relief lasting three to five months post-procedure (p<0.005).
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.